vs
Fair Isaac（FICO）とPHIBRO ANIMAL HEALTH CORP（PAHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Fair Isaacの直近四半期売上が大きい（$512.0M vs $373.9M、PHIBRO ANIMAL HEALTH CORPの約1.4倍）。Fair Isaacの純利益率が高く（30.9% vs 7.3%、差は23.6%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs 16.4%）。Fair Isaacの直近四半期フリーキャッシュフローが多い（$173.9M vs $8.3M）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs 8.6%）
FICO（旧社名Fair, Isaac and Company）は米国モンタナ州ボーズマンに本社を置くデータ分析企業で、1956年にビル・フェアとアール・アイザックにより創業されました。消費者の信用リスクを測定するFICOスコアは、米国の消費者融資業界で広く活用されています。
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
FICO vs PAHC — 直接比較
損益計算書 — Q1 FY2026 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $512.0M | $373.9M |
| 純利益 | $158.4M | $27.5M |
| 粗利率 | 83.0% | 35.5% |
| 営業利益率 | 45.7% | 13.5% |
| 純利益率 | 30.9% | 7.3% |
| 売上前年比 | 16.4% | 20.9% |
| 純利益前年比 | 3.8% | 762.1% |
| EPS（希薄化後） | $6.61 | $0.67 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $512.0M | $373.9M | ||
| Q3 25 | $515.8M | $363.9M | ||
| Q2 25 | $536.4M | $378.7M | ||
| Q1 25 | $498.7M | $347.8M | ||
| Q4 24 | $440.0M | $309.3M | ||
| Q3 24 | $453.8M | $260.4M | ||
| Q2 24 | $447.8M | $273.2M | ||
| Q1 24 | $433.8M | $263.2M |
| Q4 25 | $158.4M | $27.5M | ||
| Q3 25 | $155.0M | $26.5M | ||
| Q2 25 | $181.8M | $17.2M | ||
| Q1 25 | $162.6M | $20.9M | ||
| Q4 24 | $152.5M | $3.2M | ||
| Q3 24 | $135.7M | $7.0M | ||
| Q2 24 | $126.3M | $752.0K | ||
| Q1 24 | $129.8M | $8.4M |
| Q4 25 | 83.0% | 35.5% | ||
| Q3 25 | 82.3% | 32.9% | ||
| Q2 25 | 83.7% | 29.0% | ||
| Q1 25 | 82.4% | 30.1% | ||
| Q4 24 | 80.1% | 32.9% | ||
| Q3 24 | 80.3% | 32.1% | ||
| Q2 24 | 80.3% | 31.9% | ||
| Q1 24 | 80.0% | 30.2% |
| Q4 25 | 45.7% | 13.5% | ||
| Q3 25 | 46.0% | 14.1% | ||
| Q2 25 | 48.9% | 8.9% | ||
| Q1 25 | 49.3% | 9.6% | ||
| Q4 24 | 40.8% | 8.3% | ||
| Q3 24 | 43.4% | 6.8% | ||
| Q2 24 | 42.5% | 6.7% | ||
| Q1 24 | 44.9% | 7.6% |
| Q4 25 | 30.9% | 7.3% | ||
| Q3 25 | 30.1% | 7.3% | ||
| Q2 25 | 33.9% | 4.5% | ||
| Q1 25 | 32.6% | 6.0% | ||
| Q4 24 | 34.7% | 1.0% | ||
| Q3 24 | 29.9% | 2.7% | ||
| Q2 24 | 28.2% | 0.3% | ||
| Q1 24 | 29.9% | 3.2% |
| Q4 25 | $6.61 | $0.67 | ||
| Q3 25 | $6.41 | $0.65 | ||
| Q2 25 | $7.40 | $0.43 | ||
| Q1 25 | $6.59 | $0.51 | ||
| Q4 24 | $6.14 | $0.08 | ||
| Q3 24 | $5.44 | $0.17 | ||
| Q2 24 | $5.05 | $0.02 | ||
| Q1 24 | $5.16 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $162.0M | $74.5M |
| 総負債低いほど良い | $3.2B | $624.2M |
| 株主資本純資産 | $-1.8B | $332.4M |
| 総資産 | $1.9B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 1.88× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $162.0M | $74.5M | ||
| Q3 25 | $134.1M | $85.3M | ||
| Q2 25 | $189.0M | $77.0M | ||
| Q1 25 | $146.6M | $70.4M | ||
| Q4 24 | $184.3M | $67.1M | ||
| Q3 24 | $150.7M | $89.8M | ||
| Q2 24 | $156.0M | $114.6M | ||
| Q1 24 | $135.7M | $98.7M |
| Q4 25 | $3.2B | $624.2M | ||
| Q3 25 | $3.1B | $628.0M | ||
| Q2 25 | $2.8B | $631.7M | ||
| Q1 25 | $2.5B | $635.4M | ||
| Q4 24 | $2.4B | $639.1M | ||
| Q3 24 | $2.2B | $295.2M | ||
| Q2 24 | $2.1B | $312.1M | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $-1.8B | $332.4M | ||
| Q3 25 | $-1.7B | $311.7M | ||
| Q2 25 | $-1.4B | $285.7M | ||
| Q1 25 | $-1.1B | $266.0M | ||
| Q4 24 | $-1.1B | $246.8M | ||
| Q3 24 | $-962.7M | $258.5M | ||
| Q2 24 | $-829.3M | $256.6M | ||
| Q1 24 | $-735.7M | $270.1M |
| Q4 25 | $1.9B | $1.4B | ||
| Q3 25 | $1.9B | $1.4B | ||
| Q2 25 | $1.9B | $1.4B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.7B | $966.3M | ||
| Q2 24 | $1.7B | $982.2M | ||
| Q1 24 | $1.7B | $979.0M |
| Q4 25 | — | 1.88× | ||
| Q3 25 | — | 2.01× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | — | 2.59× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $174.1M | $19.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $173.9M | $8.3M |
| FCFマージンFCF / 売上 | 34.0% | 2.2% |
| 設備投資強度設備投資 / 売上 | 0.0% | 3.0% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 0.70× |
| 直近12ヶ月FCF直近4四半期 | $750.6M | $47.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $174.1M | $19.4M | ||
| Q3 25 | $223.7M | $9.3M | ||
| Q2 25 | $286.2M | $21.3M | ||
| Q1 25 | $74.9M | $43.2M | ||
| Q4 24 | $194.0M | $3.1M | ||
| Q3 24 | $226.5M | $12.6M | ||
| Q2 24 | $213.3M | $28.4M | ||
| Q1 24 | $71.0M | $11.4M |
| Q4 25 | $173.9M | $8.3M | ||
| Q3 25 | $219.5M | $-4.5M | ||
| Q2 25 | $284.4M | $8.1M | ||
| Q1 25 | $72.8M | $35.4M | ||
| Q4 24 | $193.2M | $-4.7M | ||
| Q3 24 | $224.7M | $3.0M | ||
| Q2 24 | $211.6M | $15.4M | ||
| Q1 24 | $67.0M | $1.7M |
| Q4 25 | 34.0% | 2.2% | ||
| Q3 25 | 42.6% | -1.2% | ||
| Q2 25 | 53.0% | 2.1% | ||
| Q1 25 | 14.6% | 10.2% | ||
| Q4 24 | 43.9% | -1.5% | ||
| Q3 24 | 49.5% | 1.2% | ||
| Q2 24 | 47.2% | 5.6% | ||
| Q1 24 | 15.4% | 0.6% |
| Q4 25 | 0.0% | 3.0% | ||
| Q3 25 | 0.8% | 3.8% | ||
| Q2 25 | 0.3% | 3.5% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 0.2% | 2.5% | ||
| Q3 24 | 0.4% | 3.7% | ||
| Q2 24 | 0.4% | 4.8% | ||
| Q1 24 | 0.9% | 3.7% |
| Q4 25 | 1.10× | 0.70× | ||
| Q3 25 | 1.44× | 0.35× | ||
| Q2 25 | 1.57× | 1.24× | ||
| Q1 25 | 0.46× | 2.07× | ||
| Q4 24 | 1.27× | 0.97× | ||
| Q3 24 | 1.67× | 1.81× | ||
| Q2 24 | 1.69× | 37.80× | ||
| Q1 24 | 0.55× | 1.36× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FICO
| Business To Business Scores | $248.6M | 49% |
| Saa S Products | $115.7M | 23% |
| Platform Software | $73.9M | 14% |
| Business To Consumer Scores | $55.9M | 11% |
| Technology Service | $19.2M | 4% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
